The mTOR signaling pathway and chronic inflammation form a central, feed-forward loop that is a primary driver of the aging process across species.
Rapamycin is the current 'gold standard' for a small molecule intervention that targets the fundamental biology of aging due to its potent effect on mTOR.
A holistic view of aging is necessary; the strategy of targeting the 12 'Hallmarks of Aging' as separate pillars is 'completely wrong' because the pathways are highly interconnected.
Current longevity interventions are poised to deliver a revolutionary 5-10 years of additional healthspan, but they are unlikely to alter the maximum human lifespan.
The efficacy of longevity supplements is highly context-dependent and requires rigorous testing, as demonstrated by the failure of NAD precursors in his lab's mice and the sex-specific effects of urolithin A.
Around 2000
The Buck Institute, the first research institute solely devoted to aging, was founded. Kennedy later served as its CEO, overseeing the creation of seven companies.
Around 2007
GSK acquired a resveratrol program, the subsequent failure of which Kennedy believes likely slowed down investor interest in the longevity sector.
Post-2013
The creation of Calico by Google's parent company Alphabet generated significant publicity for the longevity field and attracted new interest from Silicon Valley.
2017-2018
Kennedy identifies this period as a turning point when a significant increase in philanthropic and investor interest in aging and longevity research occurred.
Recently
The first international conference on 'gerophysics' was held in Singapore, signaling a new interdisciplinary approach to modeling the aging process.
Ongoing
Kennedy is involved in major human clinical trials in Singapore, including a 150-200 person study on weekly rapamycin and the analysis of a completed trial on time-release alpha-ketoglutarate (AKG).
▶The Centrality of the mTOR-Inflammation LoopApr 2026
Kennedy posits that a core mechanism of aging is a feed-forward loop where elevated baseline mTOR activity drives chronic inflammation, which in turn further stimulates mTOR signaling. He asserts that all known lifespan-extending interventions reduce this chronic inflammation, making this nexus a primary target for geroprotective strategies.
For investors, this suggests that companies developing potent and safe mTOR inhibitors or specific anti-inflammatory agents that break this cycle may represent the most promising therapeutic avenues in the longevity space.
▶Pragmatic Evaluation of Longevity MoleculesApr 2026
Kennedy's research involves rigorous testing of various compounds, yielding specific and sometimes unexpected results. While he champions rapamycin, he notes positive data for AKG and urolithin A in mice, but also reports a lack of efficacy for NAD precursors in his lab and sex-specific effects for urolithin A, underscoring a data-driven, non-dogmatic approach.
This highlights the high risk and specificity of longevity drug development; a compound's success in one model or sex doesn't guarantee broad efficacy, making a diversified portfolio approach prudent for investors.
▶Developing and Applying Models of AgingApr 2026
Kennedy's work emphasizes the creation and use of better models to understand and measure aging. This ranges from a pipeline of animal models (yeast to mice) to the development of novel biological clocks based on clinical chemistry or facial structure, and even the application of theoretical physics through a new 'gerophysics' conference.
The development of more accurate and accessible biological aging clocks represents a significant commercial opportunity, as they can serve as crucial surrogate endpoints for clinical trials, dramatically accelerating drug development.
▶The Business and Evolution of Longevity ScienceApr 2026
Kennedy provides a historical perspective on the longevity field's funding and public perception. He identifies key inflection points like the founding of the Buck Institute, the chilling effect of GSK's resveratrol failure, the publicity boom from Google's Calico, and a major surge in investor interest around 2017-2018.
The longevity sector's trajectory is sensitive to high-profile successes and failures, indicating that the results of ongoing major clinical trials, like Kennedy's own rapamycin study, could trigger the next significant wave of capital inflow or outflow.